{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-145742","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.902710+00:00","generated_at":"2026-05-18T22:31:32.749877+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Jaguar Health extends $2.57M convertible note maturity to Jan 30, 2026; issues new warrants at $2.70 strike","bullets":["Company entered Exchange Agreements with certain investors to replace ~$2.57M of 6% convertible notes originally due June 30, 2025; new maturity January 30, 2026.","Replacement Notes convertible at $5.535/sh (non-insider) or $5.555/sh (insider); New Warrants exercisable at $2.70/sh, expire in 18 months.","Insiders including CEO and board members participated in exchange, acquiring $492,012 principal of Replacement Notes and warrants for 177,138 shares.","Prior to extension, five investors converted $0.866M of original notes into equity.","Net proceeds from equity/debt financings or licensing above $8M must be used to repay Replacement Notes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-145742","json":"https://secwatch.observer/filing/0001193125-25-145742.json","markdown":"https://secwatch.observer/filing/0001193125-25-145742.md","text":"https://secwatch.observer/filing/0001193125-25-145742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525145742/0001193125-25-145742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525145742/d885397d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:31:32.749877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfa75c69eaf419779086ddf0c2be694fd0ba5e0b","claim":"Jaguar Health, Inc. incurred convertible notes of approximately $2.57 million aggregate principal amount with Participating Investors at 6% per annum maturing January 30, 2026.","evidence_excerpt":"On June 24, 2025, the Company entered into note exchange and warrant purchase agreements (the “Exchange Agreements”) with certain of the Original Investors (the “Participating Investors”), pursuant to which the Company agreed to (a) issue and sell (i) approximately $2.57 million aggregate principal amount of new 6% convertible promissory notes (the “Replacement Notes”), in exchange for the cancellation of the Original Notes held by the Participating Investors","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525145742/0001193125-25-145742-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"approximately $2.57 million aggregate principal amount"},{"label":"Counterparty","value":"Participating Investors"},{"label":"Rate","value":"6% per annum"},{"label":"Maturity","value":"January 30, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}